Bill Information > SB 5020
Search for another bill or initiative:
SB 5020 - 2021-22
Assessing a penalty on unsupported prescription drug price increases to protect the safety, health, and economic well-being of Washington residents.
Sponsors: Keiser, Robinson, Conway, Das, Hasegawa, Kuderer, Lovelett, Rolfes, Stanford, Van De Wege, Wilson, C.
2021 REGULAR SESSION
Prefiled for introduction.
First reading, referred to Health & Long Term Care. (View Original Bill)
Public hearing in the Senate Committee on Health & Long Term Care at 8:00 AM. (Committee Materials)
Executive action taken in the Senate Committee on Health & Long Term Care at 8:00 AM. (Committee Materials)
HLTC - Majority; 1st substitute bill be substituted, do pass. (View 1st Substitute) (Majority Report)
Minority; do not pass. (Minority Report)
Minority; without recommendation. (Minority Report)
And refer to Ways & Means.
Referred to Ways & Means.
2022 REGULAR SESSION
By resolution, reintroduced and retained in present status.
For a complete list of documents, go to Online Reports Text of a Legislative Document.